摘要
目的对某院使用丹参多酚酸盐治疗急性脑梗死的情况进行调研,对用药合理性和安全性进行评价。方法采用回顾分析方法,收集了2015～2017年该院使用丹参多酚酸盐治疗急性脑梗死患者共87例,对用药数据进行统计分析,包括患者一般信息、诊断、神经功能缺损评分、用法用量、疗程、联合用药、用药前后肝肾功能指标和不良反应等,同时进行合理性评价。结果丹参多酚酸盐的使用科室主要为心内科(75.13%)和神经内科(12.76%);目前丹参多酚酸盐治疗急性脑梗死均为超说明书用药; 9.2%病例用药日剂量低于说明书推荐剂量; 79.31%病例给药疗程≤7 d; 64.37%病例在发病1周后启用; 75.86%病例与活血祛瘀类中成药联用; 96.55%病例同时使用多种静脉注射液;使用多集中在预后良好的患者(NIHSS<6分);用药前后患者肝肾安全性未见明显影响。结论该药治疗急性脑梗死为超适应证用药,存在日剂量偏小、疗程不足、联合用药随意的情况,临床应严格把握该药适应证和用法,保障患者用药安全。
OBJECTIVE To investigate the rationality and safety of Salvianolate in the treatment of acute cerebral infarction.METHODS 87 cases of acute cerebral infarction treated with salvianolate in the hospital from 2015 to 2017 were analyzed retrospectively.The medication data,including general information,diagnosis,neurological deficit score,usage and dosage,course of treatment,combination therapy,liver and kidney function indicators before and after administration and ADR were performed to statistical analysis and the rationality evaluation. RESULTS The hospital’s department using salvianolate was mainly concentrated in cardiology( 75.13%) and neurology( 12.76%).At present,the salvianolate for acute cerebral infarction was mainly for off-label use.9.2% cases had a daily dose lower than the recommended dose.79.31% cases were treated for ≤7 days. 64.37% cases started to used salvianolate one week after onset. 75. 86% cases were combined with blood stasis the main Chinese medicines. 96. 55% cases used a variety of intravenous injections simultaneously. The use of salvianolate during hospitalization was mostly concentrated in patients with good prognosis( NIHSS <6).No significant effect on liver and kidney safety of patients before and after treatment. CONCLUSION The salvianolate for acute cerebral infarction is mainly for off-label use. There are inadequate dosing,insufficiency of period of treatment,drugs using at will and so on.To ensure patients’ medication safety,the indications and usage of the drug should be strictly controlled in clinic.
作者
黄志恩
李晓莹
李艳秋
刘俊娥
姚晖
HUANG Zhien;LI Xiaoying;LI Yanqiu;LIU june;YAO Hui(Department of Clincal Pharmacy. The Second People'sHospital of Foshan,Foshan,Guangdong 528000,China;Department of Neurology,The Second People's Hospital of' Foshan,Foshan,Guangdong 528000,China)
出处
《今日药学》
CAS
2019年第2期108-112,共5页
Pharmacy Today
基金
佛山市卫生和计划生育局医学科研课题(20160127)
佛山市十三五医学重点专科建设项目(FSZDZK135025)
关键词
丹参多酚酸盐
急性脑梗死
用药评价
Salvianolate
acute cerebral infarction
drug evaluation
